Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTAPLEX for acute major bleeding on factor Xa inhibitor DOACs
2024-515485-14-00Phase 3Completed
- Sponsor
- Octapharma
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of coagulation factor X human in Acute major hemorrhage (2 arms), sponsored by Octapharma. Primary endpoint: Haemostatic effectiveness of OCTAPLEX. Started Aug 2024; status: completed.
02
Drugs
coagulation factor X human
03
Conditions
Acute major hemorrhage
Beyond the preview
Go deeper on 2024-515485-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515485-14-00.